Analysts take a look at Nevro Corp. (NYSE:NVRO) having this to say.

January 10, 2018 - By Henry Gaston

 Analysts take a look at Nevro Corp. (NYSE:NVRO) having this to say.

Nevro Corp. (NYSE:NVRO) Ratings Coverage

Among 13 analysts covering Nevro Corp (NYSE:NVRO), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. Nevro Corp had 29 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Sunday, October 8. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, November 7 report. William Blair initiated the stock with “Outperform” rating in Tuesday, July 19 report. BMO Capital Markets initiated it with “Outperform” rating and $65 target in Friday, September 25 report. Northland Capital upgraded the stock to “Outperform” rating in Monday, January 30 report. The rating was maintained by BMO Capital Markets with “Buy” on Tuesday, June 6. BMO Capital Markets maintained Nevro Corp. (NYSE:NVRO) on Thursday, August 31 with “Buy” rating. Canaccord Genuity initiated the stock with “Buy” rating in Thursday, March 23 report. The company was maintained on Tuesday, August 8 by Morgan Stanley. Canaccord Genuity maintained Nevro Corp. (NYSE:NVRO) on Wednesday, July 5 with “Buy” rating. Below is a list of Nevro Corp. (NYSE:NVRO) latest ratings and price target changes.

12/12/2017 Broker: BMO Capital Markets Rating: Buy New Target: $100.0 Maintain
07/11/2017 Broker: Leerink Swann Rating: Outperform Old Target: $105 New Target: $110 Maintain
07/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $120 New Target: $110 Maintain
08/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $120.0 Maintain
31/08/2017 Broker: BMO Capital Markets Rating: Buy New Target: $106.0 Maintain
08/08/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $87 New Target: $95 Maintain
08/08/2017 Broker: Northland Capital Rating: Buy New Target: $96.0000 Maintain
06/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $120.0000 Maintain
11/07/2017 Broker: BMO Capital Markets Rating: Buy New Target: $106.0000 Maintain

The stock increased 0.28% or $0.2201 during the last trading session, reaching $78.0901. About 494,666 shares traded or 7.13% up from the average. Nevro Corp. (NYSE:NVRO) has risen 14.69% since January 10, 2017 and is uptrending. It has underperformed by 2.01% the S&P500.

Nevro Corp., a medical device company, focuses on providing products for the patients suffering from chronic pain in the United States and internationally. The company has market cap of $2.31 billion. It develops and commercializes the Senza spinal cord stimulation system, an evidence neuromodulation platform for the treatment of chronic pain. It currently has negative earnings. The firm sells its products through its direct sales force, and a network of sales agents and independent distributors.

More news for Nevro Corp. (NYSE:NVRO) were recently published by: Nasdaq.com, which released: “Mid-Day Market Update: Dave & Buster’s Drops On Lowered Outlook; Nevro Shares …” on January 08, 2018. Nasdaq.com‘s article titled: “Nevro Corp. (NVRO) Is Up Sharply After FDA Approval” and published on January 08, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.